Drugs / Prevenar 20
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT06822907 | Dec 2025 → Oct 2028 expected | pneumococcal infection | University Hospital of Saint-Etienne | Recruiting | No outcome recorded |
| Phase 4 | NCT04460235 | Sep 2021 → Jun 2028 expected | non-Hodgkin lymphoma, pneumococcal infection | Poitiers University Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07160244 Background | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-13 | Pfizer | Regulatory European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20 ® , for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-13 | Pfizer | European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prevenar 20 | “The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.” NCT06822907 ↗ |
| Modality | Vaccine | “PREVENAR20 vaccine” NCT04460235 ↗ |
| Route | Intramuscular | “Prevenar 20 will be injected by intramuscular route.” NCT06822907 ↗ |